TITLE:
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer

CONDITION:
Colorectal Cancer

INTERVENTION:
5 FU

SUMMARY:

      This 2 arm study will assess the efficacy and safety of intermittent oral Xeloda, or iv
      fluorouracil/leucovorin, in combination with intravenous Eloxatin (oxaliplatin) in patients
      previously treated for metastatic colorectal cancer. Patients will be randomized to receive
      either 1)XELOX (Xeloda 1000mg/m2 po bid on days 1-15 + oxaliplatin) in 3 week cycles or 2)
      FOLFOX-4 (oxaliplatin + leucovorin + 5-FU in 2 week cycles. The anticipated time on study
      treatment is until disease progression, and the target sample size is 500+ individuals.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  adult patients >=18 years of age;

          -  metastatic colorectal cancer;

          -  >=1 target lesion;

          -  failed first-line chemotherapy with 5-fluorouracil and irinotecan.

        Exclusion Criteria:

          -  previous treatment with oxaliplatin;

          -  progressive or recurrent disease during or within 6 months of completion of
             first-line chemotherapy;

          -  >=1 previous chemotherapeutic agent or systemic anticancer regimen for metastatic
             disease.
      
